key: cord-0831803-xxm6o1l1
authors: Dejnirattisai, Wanwisa; Zhou, Daming; Supasa, Piyada; Liu, Chang; Mentzer, Alexander J.; Ginn, Helen M.; Zhao, Yuguang; Duyvesteyn, Helen M.E.; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Wang, Beibei; Paesen, Guido C.; López-Camacho, César; Slon-Campos, Jose; Walter, Thomas S.; Skelly, Donal; Costa Clemens, Sue Ann; Naveca, Felipe Gomes; Nascimento, Valdinete; Nascimento, Fernanda; Fernandes da Costa, Cristiano; Resende, Paola C.; Pauvolid-Correa, Alex; Siqueira, Marilda M.; Dold, Christina; Levin, Robert; Dong, Tao; Pollard, Andrew J.; Knight, Julian C.; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah; Carroll, Miles W.; Klenerman, Paul; Barnes, Eleanor; Dunachie, Susanna J.; Paterson, Neil G.; Williams, Mark A.; Hall, David R.; Hulswit, Ruben J.G.; Bowden, Thomas A.; Fry, Elizabeth E.; Mongkolsapaya, Juthathip; Ren, Jingshan; Stuart, David I.; Screaton, Gavin R.
title: Antibody evasion by the P.1 strain of SARS-CoV-2
date: 2021-03-30
journal: Cell
DOI: 10.1016/j.cell.2021.03.055
sha: 3b173e15c92b120d35e8643d739e46e4a4d618b7
doc_id: 831803
cord_uid: xxm6o1l1

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations: P.1 from Brazil, B.1.351 from South Africa and B.1.1.7 from the UK (12, 10 and 9 changes in the spike respectively). All have mutations in the ACE2 binding site with P.1 and B.1.351 having a virtually identical triplet: E484K, K417N/T and N501Y, which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine induced antibody responses than B.1.351 suggesting that changes outside the RBD impact neutralisation. Monoclonal antibody 222 neutralises all three variants despite interacting with two of the ACE2 binding site mutations, we explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

For more than a year SARS-CoV-2 has caused enormous global dislocation, leading to more 72 than 2.5 million deaths (https://www.worldometers.info/coronavirus Accessed: 2021-03-01) 73 and leaving no country untouched. Successive waves of infection have led to the imposition 74 of draconian lock downs in many countries resulting in severe economic and societal 75 disruption (Donthu and Gustafsson, 2020) .

RNA, viral vectors, recombinant protein and inactivated (Krammer, 2020) . Five vaccines 80 have now been through large scale phase III trials and have demonstrated safety and efficacy 81 (Polack et al., 2020; Voysey et al., 2020; Baden et al., 2020) . Four of these, BNT162b2 from the first reported sequence from Wuhan in January 2020 . the pandemic which is largely uncontrolled leads to huge levels of viral replication, 95 increasing the chances that adaptive mutations will occur. There are many possible ways 96 whereby a mutation in SARS-CoV-2 may give the virus a selective advantage, however 97 concentrating on mutation in S, there are two clear possibilities: increased efficiency of 98 transmission and escape from neutralizing antibodies (Volz et al., 2021) .

The S protein is a large Type-1 transmembrane glycoprotein which assembles into homo-101 trimers , which form most of the outer surface of coronaviruses. S is 102 cleaved by proteolysis to form S1 and S2, S1 is responsible for target cell engagement, whilst 103 S2 completes membrane fusion allowing the viral RNA access to the host cell cytoplasm 104 J o u r n a l P r e -p r o o f In this paper we examine an isolate of P.1 cultured from a throat swab taken from an infected 130 patient in Manaus, Brazil in December 2020 and compare its interactions with serum and 131 antibodies with those of three other viruses, an early isolate, B.1. 1.7 and B.1.351 . We test the 132 ability of immune sera induced by infection with early strains of SARS-CoV-2 (Dejnirattisai 133 et al., 2021) , or by vaccination with the Oxford-AstraZenca or Pfizer-BioNTech vaccines to 134 neutralize P.1 Zhou et al., 2021) . We see a reduction in the neutralizing 135 capacity of immune serum to P.1 similar to the reduction seen with B.1.1.7, but not as severe 136 as that seen with B.1.351 . We demonstrate an increased affinity of P.1 137 RBD for ACE2 and investigate the structural basis of this through crystallography. We also December 2020 leading to further hospitalizations. This second wave corresponded with the 155 rapid emergence of P.1, not seen before December when it was found in 52% of cases, rising 156 to 85% by January 2021 (Figure S1 ).

N501Y in the RBD, D614G and H655Y at the C-terminus of S1 and T1027I, V1176F in S2.

The position of the changes seen in P.1 compared with those found in B. 1.1.7 and B.1.351 163 together with a representation on where they occur on the full spike protein and RBD are 164 shown in Figure 1 . Mutations K417T, E484K, N501Y in the ACE2 interacting surface are of 165 the greatest concern because of their potential to promote escape from the neutralizing 166 antibody response which predominately targets this region ( Figure 1D ) (Dejnirattisai et al., 167 2021). We searched the COVID-19 genomics UK (COG-UK) (Tatusov et al., 2000) Of note, two of the NTD changes in P.1 introduce N-linked glycosylation sequons T20N 177 (TRT to NRT) and R190S (NLR to NLS, Figure 1E ). The NTD, in the absence of these 178 changes, reasonably well populated with glycosylation sites, indeed it has been suggested that a single bare patch surrounded by N-linked glycans attached at N17, N74, N122, and N149 180 defines a 'supersite' limiting where neutralizing antibodies can attach to the NTD (Cerutti et 181 al., 2021) . Residue 188 is somewhat occluded whereas residue 20 is highly exposed, is close 182 to the site of attachment of neutralizing antibody 159 and impinges 183 on the proposed NTD supersite.

The effects of RBD mutations on ACE2 affinity. 186 We have previously measured the affinity of RBD/ACE2 interaction for Wuhan, B. To better understand RBD-ACE2 interactions we determined the crystal structure of the P.1 195 RBD-ACE2 complex at 3.1 Å resolution (Methods , Table S1 ). As expected the mode of Residue 417 lies at the back of the RBD neck (our RBD anatomy follows Dejnirattisai et al., 204 2021) and in the original SARS-CoV-2 is a lysine residue which forms a salt-bridge with D30 205 of ACE2 ( Figure 2E ). The threonine of P.1 RBD no longer forms this interaction and the gap 206 created is open to solvent, so there is no obvious reason why the mutation would increase 207 affinity for ACE2, and this is consistent with directed evolution studies (Zahradník et al., 208 2021) where this mutation was rarely selected in RBDs with increased affinity for ACE2. found that compared to Victoria (SARS-CoV-2/human/AUS/VIC01/2020), an early isolate of 227 SARS-CoV-2, which has a single change S247R in S compared to the Wuhan strain 228 J o u r n a l P r e -p r o o f Caly et al., 2020) Figure 2J and reflects direct interaction with mutated residues. Of 234 note is mAb 222 which maintains binding potency across all variants despite adjacency to 235 mutated residues, as discussed below. . There is good correlation between the negative impact on 245 neutralization and on RBD-affinity, as shown in Figure 2J where the impact on each is 246 shown as a colour ramp from zero (white) to 1000-fold (red). therapeutically or prophylactically (Ku et al., 2021; Baum et al., 2020; Kemp et al., 2021) . We 251 performed neutralization assays against P.1 using antibodies S309 Vir (Pinto et al., 2020) , Figure 4A ) . Residues 20, 18 and 138 281 form a cluster underlying the 245-259 loop which inserts into a groove between the light and 282 heavy chains of Fab 159 ( Figure 4A ). In addition, the N-terminal residues preceeding residue 283 18 interact with the antibody and may be perturbed. It is also conceivable that the failure of 284 this antibody to achieve complete neutralization could be due to partial glycosylation at 285 residue 20, which is some 16 Å from bound Fab 159. Since it has been proposed that there is 286 a single supersite for potent NTD binding antibodies we would expect the binding of many of 287 these to be affected . Five of the potent monoclonal antibodies used in this study (150, 158, 175, 222 and 269) , 291 belong to the VH3-53 family and a further 2 (out of 5 of this family) belong to the almost 292 identical VH3-66, and the following discussion applies also to these antibodies. The binding 293 sites for these have been described . The large majority of these 294 antibodies attach to the RBD in a very similar fashion. These motifs recur widely, VH3-53 295 are the most prevalent deposited sequences and structures for SARS-CoV-2 neutralizing 296 antibodies. Their engagement with the RBD is dictated by CDR-H1 and CDR-H2 whilst the 297 CDR-H3 is characteristically short and makes rather few interactions (Yuan et al., 2020;  298 Barnes et al., 2020; Dejnirattisai et al., 2021) . We have previously solved the structures of (Table S2) . Figure 6B and D, Table S4B ). The ACE2 interacting surface of RBD is a small 25 amino acid patch at the apex of S and is 425 under extreme selection pressure as it not only mediates interaction with the cellular receptor 426 but is also the site of binding for a major class of neutralizing antibodies that block the interaction of ACE2 with the RBD (Zost et al., 2020; Kreye et al., 2020; Wu et al., 2020; Yuan 428 et al., 2020; Dejnirattisai et al., 2021) . Recently, two elegant unbiased approaches have been 429 used to assess the influence of mutation on the ACE2/RBD binding affinity or the ability of 430 RBD mutations to evade the polyclonal antibody response. Firstly, a yeast display approach 431 was used to generate RBD mutants with enhanced ACE2 binding. Amongst a number of 432 mutations selected were the very same positions found in the recent variants of concern, 433 namely E484K and N501Y, and less frequently changes at residue 417 were also observed 434 (Zahradník et al., 2021) . Multiple rounds of selection led to the emergence of mutant RBDs 435 with 600-fold higher affinity to ACE2, in the low picomolar range. In a second approach, 436 polyclonal anti-SARS-CoV-2 serum was used to select mutant RBD from a yeast display 437 library which showed reduced antibody binding (Greaney et al., 2021) . This approach led to 438 the identification of a number of potential antibody escape mutants, amongst them E484K 439 which is likely responsible for a proportion of the escape from antibody neutralization we 440 describe for P.1. natural responses against all three variants, and common cross-protective responses, will be 505 found.

The recent emergence of a number of variants of concern has led to efforts to design new 508 vaccines which will be able to protect against the viral variants. Exactly which variants or In summary, we demonstrate that P.1 can escape neutralization by a number of monoclonal 517 antibodies including some being developed for prophylactic or therapeutic use, while other 518 antibodies with epitopes away from the mutated RBD residues retain broad neutralization.

Thus S309/AZD1061/REGN10987/ADG10/ADG20/ADG30 showed little to no reduction 520 (<4-fold) in neutralization activity across the three variants, consistent with their previously 521 described broadly neutralizing activities across clade I sarbecoviruses. with vaccines designed against parent/ancestral strains will provide protection from P.1.

The in vitro FRNT assays we report here do not measure the effect of complement or Table S2 . reported Zhou et al., 2021) . FRNT50 titres are reported in Table S2 645 Neutralization curves for monoclonal antibodies in different stages of development for Figure S3 and Table S3 . Table S2 . tailed P values were calculated, geometric mean values are indicated above each column.

Relevant data are shown in Table S5 . 

RBD/ACE2 were mounted in loops and dipped in solution containing 25% glycerol and 75% 867 mother liquor for a second before being frozen in liquid nitrogen prior to data collection.

Diffraction data were collected at 100 K at beamline I03 of Diamond Light Source, UK. All with the automated data processing program Xia2-dials (Winter, 2010; Winter et al., 2018) . A 876 data set of 1080° was collected from 3 positions of a frozen crystal for the WT RBD-EY6A- structure refinement statistics are given in Table S1 . Structural comparisons used SHP 891 (Stuart et al., 1979) , residues forming the RBD/Fab interface were identified with PISA 892 (Krissinel and Henrick, 2007) 

Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS), 2 727 mM GlutaMAX (Gibco, 35050061) and 100 U/ml of penicillin-streptomycin. Human mAbs 728 were expressed in HEK293T cells cultured in UltraDOMA PF Protein-free Medium (Cat# 729 12-727F, LONZA) at 37 °C with 5% CO 2 . E.coli DH5α bacteria were used for transformation 730 of plasmids encoding wt and mutated RBD proteins. A single colony was picked and cultured 731 in LB broth with 50 µg mL -1

Sigma-Aldrich) 733 supplemented with 10% FBS, 1% 100X Mem Neaa (Gibco) and 1% 100X L-Glutamine 734 (Gibco) at 37 °C with 5% CO 2 . To express RBD, RBD K417T, E484K, N501Y, RBD 735 K417N, RBD K417T, RBD E484K and ACE2, HEK293T cells were

Participants were recruited through three studies: Sepsis Immunomics

Emerging Infections [Oxford REC C, reference 13/SC/0149] and the Gastro-intestinal illness 742 in Oxford: COVID sub study

RT-PCR) from an upper 745 respiratory tract (nose/throat) swab tested in accredited laboratories. A blood sample was 746 taken following consent at least 14 days after symptom onset. Clinical information including 747 severity of disease (mild, severe or critical infection according to

World Health Organisation) and times between symptom onset and sampling and age of 749 participant was captured for all individuals at the time of sampling

Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Viral quasispecies

Effects of COVID-19 on business and research

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against

Coot: Model-building tools for molecular graphics

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology -Virological, virological.org

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 evolution during treatment of chronic infection

SARS-CoV-2 vaccines in development

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Inference of Macromolecular Assemblies from Crystalline State

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccine against the B.1.351 variant in South Africa

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Phaser crystallographic software

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Tracking the COVID-19 pandemic in Australia using genomics

Structural basis of receptor recognition by SARS-CoV-2

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

The COG database: A tool for genome-scale analysis of protein functions and evolution

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

V2 escapes neutralization by South African COVID-19 donor plasma

Xia2: An expert system for macromolecular crystallography data reduction

DIALS : J o u r n a l P r e -p r o o f implementation and evaluation of a new integration package

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Structural basis of a shared antibody response to SARS-CoV-2

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

Potently neutralizing and protective human antibodies against SARS-CoV-2

Despite similar RBD mutations P.1 is easier to neutralize than B.1.351

351 and B.1.1.7 partially or fully escape most VH3-53 antibodies

VH3-53) retains neutralisation against all 3 variants

Neutralisation is restored in VH3-53 chimeric antibodies with mAb 222 LC

Structural and functional analysis of the P.1 variant of SARS-CoV-2 from Brazil reveals less resistance to antibodies generated from natural infection or vaccination compared to another similar variant, B.1.351. A monoclonal antibody mAb 222 is able to neutralize all three variants

Protein production was as described in Zhou et al. (Zhou et al., 2020) . Briefly, plasmids 827 encoding proteins were transiently expressed in HEK293T (ATCC CRL-11268) cells. The 828 conditioned medium was dialysed and purified with a 5-ml HisTrap nickel column (GE 829 Healthcare) and further polished using a Superdex 75 HiLoad 16/60 gel filtration column (GE ACE2 was mixed with P.1 RBD in a 1:1 molar ratio to a final concentration of 12.5 mg ml −1 .

EY6A Fab, 222 Fab and WT or mutant RBD were mixed in a 1:1:1 molar ratio to a final